KETOTIFEN

Clinical Indication

Mast Cell Activation Syndrome (MCAS)

Date of classification

July 2020

Review date

July 2020

Amber SIMPLE

Drugs suitable to be initiated and prescribed in primary care only after specialist assessment and recommendation. A shared care agreement is not required.